References
- GOLDGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2015 Available from: http://www.goldcopd.com/Accessed August 12, 2015
- DransfieldMTBaileyWCraterGEmmettAO’DellDMYawnBDisease severity and symptoms among patients receiving monotherapy for COPDPrim Care Respir J2011201465320886200
- SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol201579569570825377687
- DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
- CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
- Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
- ObaYSarvaSTDiasSEfficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
- DecramerMAnzuetoAKerwinEEfficacy and safety of umecli-dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
- JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
- DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
- SchmidtSAJohansenMBOlsenMThe impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort studyBMJ Open2014412e006720
- SinDDManSFChronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortalityProc Am Thorac Soc20052181116113462
- SinDDWuLManSFThe relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literatureChest200512761952195915947307
- TockmanMSPearsonJDFlegJLRapid decline in FEV1. A new risk factor for coronary heart disease mortalityAm J Respir Crit Care Med19951512 Pt 13903987842197
- JonesPWLamarcaRChuecosFCharacterisation and impact of reported and unreported exacerbations: results from ATTAINEur Respir J20144451156116525234803
- WilkeSJonesPWMullerovaHOne-year change in health status and subsequent outcomes in COPDThorax201570542042525782757
- DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
- WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
- CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
- Garcia-RioFRojoBCasitasRPrognostic value of the objective measurement of daily physical activity in patients with COPDChest2012142233834622281798
- VaesAWGarcia-AymerichJMarottJLChanges in physical activity and all-cause mortality in COPDEur Respir J20144451199120925063247
- WaschkiBSpruitMAWatzHPhysical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter studyRespir Med2012106452253022118987
- WatzHWaschkiBMeyerTMagnussenHPhysical activity in patients with COPDEur Respir J200933226227219010994
- SinghDZhuCQSharmaSChurchAKalbergCJDaily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover studyPulm Pharmacol Ther201531859125197005